- Astressin-B
-
- $0.00 / 1gram
-
2023-11-27
- CAS:170809-51-5
- Min. Order: 1gram
- Purity: 99%
- Supply Ability: 20 tons
- ASTRESSIN
-
- $7.00 / 1KG
-
2020-02-14
- CAS:170809-51-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| | ASTRESSIN Basic information |
| Product Name: | ASTRESSIN | | Synonyms: | H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2;M.W. 3563.24 C161H269N49O42;DPHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-GLU-ALA-HIS-LYS-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2;D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 (LactaM bridge Glu30-Lys33);H-D-PHE-HIS-LEU-LEU-ARG-GLU-VAL-LEU-GLU-NLE-ALA-ARG-ALA-GLU-GLN-LEU-ALA-GLN-CYCLO(-GAMMA-GLU-ALA-HIS-EPSILON-LYS)-ASN-ARG-LYS-LEU-NLE-GLU-ILE-ILE-NH2;[D-PHE12, NLE21,38, GLU30, LYS33]-CORTICOTROPIN RELEASING FACTOR (12-41) (HUMAN, RAT);[D-PHE12,NLE21,38,GLU30,LYS33]-CORTICOTROPIN RELEASING FACTOR FRAGMENT 12-41;[D-PHE12, NLE21,38, GLU30, LYS33]-CRF (12-41), CYCLIC LACTAM, HUMAN, RAT | | CAS: | 170809-51-5 | | MF: | C161H269N49O42 | | MW: | 3563.16 | | EINECS: | 617-559-7 | | Product Categories: | CRF receptor and related | | Mol File: | 170809-51-5.mol |  |
| | ASTRESSIN Chemical Properties |
| density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | form | Powder | | Water Solubility | Soluble to 1 mg/ml in 10% Acetic acid / water | | Sequence | H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 |
| | ASTRESSIN Usage And Synthesis |
| Uses | Astressin has been used as a CRF-receptor antagonist to study its effects on the decrease in the Schaffer collateral-CA1 field potential induced by hypoxia/hypoglycemia (ischemia) in rat hippocampal slices. | | Definition | ChEBI: A 30-membered homodetic cyclic peptide comprising the sequence D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 cyclised by an amide bridge,
ormed by condensation of the side-chain carboxy group of the Glu residue at position 19 and the side-chain amino group of the Lys residue at position 22. | | Biochem/physiol Actions | Astressin is a non-selective corticotropin releasing factor (CRF)-receptor antagonist. It potentially blocks CRF-induced adrenocorticotropic hormone (ACTH) release. Astressin effectively deceases delayed effects of chronic social isolation such as anxiety and fobial states in rats. | | Enzyme inhibitor | This novel CRF antagonist (MW = 3663.20 g/mol; CAS 170809-51-5; Sequence: D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala- Glu-Gln-Ala-Gln-cyclo-(g-Glu-Ala-His-e-Lys)Asn-Arg-Leu-Leu-Mle-Glu- Ile-Ile-NH2; Solubility: 1 mg/mL in Acetic acid/water (10% vol/vol); Alternate Name: [D-Phe 12 , Nle 21,38 , Glu30 , Lys 33 ]-CRF) targets human Corticotropin-Releasing hormone (CRH) Receptor subtypes CRF2α (Ki = 1.5 nM) and CRF2β (Ki = 1 nM), with a comparable value (2 nM) for CRF1. (See also Antisauvagine-30; K41448) These type-2 GPCRs reside in plasma membranes of hormone-sensitive cells and bind CRH, a peptide hormone and neurotransmitter involved in stress responses. Astressin is a structurally constrained and competitive antagonists of corticotropin- releasing factor. Astressin is neuroprotective in the hippocampus when administered after a seizure. Peripheral injection of astressin blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats. A related antagonist is Astressin 2B (FW = 4041.69 g/mol; CAS 681260-70-8; Sequence: Ac-Asp-Leu-Ser-D-Phe-His-a-methyl-Leu-Leu- Arg-Lys-Nle-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala- cyclo-(g-Glu-Ala-Asn-e-Lys)Leu-Leu-Leu-Asp-a-methyl-Leu-Ile-NH2). Astressin 2B is a potent and selective antagonist of CRF2 (IC50 = 1.3 nM) and CRF1 (IC50 > 500 nM). | | storage | Store at -20°C |
| | ASTRESSIN Preparation Products And Raw materials |
|